Literature DB >> 6166575

Interferon and spontaneous cytotoxicity in man. V. Enhancement of spontaneous cytotoxicity in patients receiving human leukocyte interferon.

S Einhorn, H Blomgren, H Strander.   

Abstract

The effect of daily injections of 3 x 10(6) units of human leukocyte IF on the spontaneous cytotoxicity of peripheral lymphocytes was studied in 43 patients with a variety of diseases. An increase in spontaneous cytotoxicity was observed 12 to 24 h after the first IF injection with the peak of activity occurring, in most cases, at 24 h. In some patients a decrease in spontaneous cytotoxicity, observed 6 h after the injection, preceded this increase. The increment in spontaneous cytotoxicity was not significantly correlated to preinjection level of cytotoxicity, disease, age, sex, previous therapy, leukocyte counts or proportions of lymphocytes and monocytes. A second injection of IF maintained the spontaneous cytotoxicity at an increased level and during prolonged IF therapy, up to 9 months, the cytotoxicity remained elevated. IF treatment in vitro caused an enhancement of spontaneous cytotoxicity in lymphocytes drawn prior to IF injection. This IF-induced increase in cytotoxicity in vitro was correlated to the increase in cytotoxicity induced by IF in vivo. Six hours after the first IF injection the ability of IF in vitro to enhance spontaneous cytotoxicity was decreased and during prolonged therapy the ability of IF in vitro to enhance spontaneous cytotoxicity remained decreased.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6166575     DOI: 10.1002/ijc.2910260406

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

1.  Influence of alpha-interferon therapy on blood lymphoid cells. Studies on antibody production, mixed lymphocyte culture response, mitogen responsiveness and 2'-5'oligoadenylate synthetase activity.

Authors:  S Einhorn; P Ling; N Einhorn; H Strander; J Wasserman
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  Enhancement of defective monocyte function during immunotherapy with recombinant interferon.

Authors:  H Nielsen; P Ernst
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Application of a new method for detecting the phenotype of target binding cells.

Authors:  R A Lindemann; J A Jenkins; R A Figlin; S H Golub
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 4.  Interferons and interferon inducers: development of clinical usefulness and therapeutic promise.

Authors:  R B Pollard
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

5.  Effects of activated T cells on natural killing.

Authors:  R A Knight; P Fitzharris
Journal:  Immunology       Date:  1982-03       Impact factor: 7.397

6.  Decreased NK killing in patients with multiple sclerosis: an analysis on the level of the single effector cell in peripheral blood and cerebrospinal fluid in relation to the activity in the disease.

Authors:  J Merrill; M Jondal; J Seeley; M Ullberg; A Sidén
Journal:  Clin Exp Immunol       Date:  1982-02       Impact factor: 4.330

7.  Low doses of interferon alpha result in more effective clinical natural killer cell activation.

Authors:  B S Edwards; J A Merritt; R C Fuhlbrigge; E C Borden
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

8.  Influence of human interferon-alpha therapy on cytotoxic functions of blood lymphocytes. Studies on lectin-dependent cellular cytotoxicity, antibody-dependent cellular cytotoxicity, and natural killer cell activity.

Authors:  S Einhorn; H Blomgren; H Strander; J Wasserman
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

9.  Clinical and immunological evaluation of 20 patients with advanced colorectal cancer treated with high dose recombinant leukocyte interferon-alpha A (rIFN alpha A).

Authors:  A M Eggermont; W Weimar; B Tank; A M Dekkers-Bijma; R L Marquet; J S Lameris; D L Westbroek; J Jeekel
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

10.  Decrease in the phagocytic activity of peripheral monocytes in patients treated with human interferon-alpha.

Authors:  S Einhorn; C Jarstrand
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.